Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis

Journal of Cachexia, Sarcopenia and Muscle

Volumn 7, Issue 2, 2016, Pages 126-135

  Montano Loza, Aldo J ^a   Angulo, Paul ^b   Meza Junco, Judith ^c   Prado, Carla M M ^d   Sawyer, Michael B ^c   Beaumont, Crystal ^c   Esfandiari, Nina ^c   Ma, Mang ^a   Baracos, Vickie E ^c  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c CROSS CANCER INSTITUTE   (Canada)

^d Food and Nutritional Sciences ^*  (Canada)

Author keywords

Cirrhosis; Lumbar skeletal muscle index; Muscle attenuation index; Muscle depletion; Myosteatosis; Overweight

Indexed keywords

ALBUMIN; ALCOHOL; BILIRUBIN; CREATININE; SODIUM;

ADULT; AGE; ARTICLE; AUTOIMMUNE LIVER DISEASE; BACTERIAL INFECTION; BLEEDING; BODY WEIGHT; CEREBROVASCULAR DISEASE; CHILD PUGH SCORE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GENDER; HEART ARREST; HEPATITIS B; HEPATITIS C; HEPATORENAL SYNDROME; HUMAN; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; MUSCLE ATTENUATION; MUSCULOSKELETAL SYSTEM PARAMETERS; MYOSTEATOSIS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROGNOSIS; SARCOPENIA; SARCOPENIC OBESITY; SEPSIS; STEATOSIS; SURVIVAL; VARICEAL BLEEDING;

EID: 84973259132     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1002/jcsm.12039     Document Type: Article

References (42)

1. Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in developing countries. Nutr Rev 2012; 70: 3-21.
2. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology 2007; 132: 2087-102.
3. Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL, Chung RT, et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 2009; 137: 549-57.
4. Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput JC, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002; 35: 635-8.
5. Berzigotti A, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Morillas R, et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology 2010; 54: 555-61.
6. Meza-Junco J, Montano-Loza AJ, Baracos VE, Prado CM, Bain VG, Beaumont C, et al. Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. J Clin Gastroenterol 2013; 47: 861-70.
7. Kaido T, Ogawa K, Fujimoto Y, Ogura Y, Hata K, Ito T, et al. Impact of sarcopenia on survival in patients undergoing living donor liver transplantation. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2013; 13: 1549-56.
8. Krell RW, Kaul DR, Martin AR, Englesbe MJ, Sonnenday CJ, Cai S, et al. Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation. Liver Transpl 2013; 19: 1396-402.
9. Englesbe MJ, Patel SP, He K, Lynch RJ, Schaubel DE, Harbaugh C, et al. Sarcopenia and mortality after liver transplantation. J Am Coll Surg 2010; 211: 271-8.
10. Montano-Loza AJ, Meza-Junco J, Prado CM, Lieffers JR, Baracos VE, Bain VG, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2012; 10: 166-73.
11. Johnson TM, Overgard EB, Cohen AE, DiBaise JK. Nutrition assessment and management in advanced liver disease. Nutr Clin Pract 2013; 28: 15-29.
12. O'Brien A, Williams R. Nutrition in end-stage liver disease: principles and practice. Gastroenterology 2008; 134: 1729-40.
13. Montano-Loza AJ. New concepts in liver cirrhosis: clinical significance of sarcopenia in cirrhotic patients. Minerva Gastroenterol Dietol 2013; 59: 173-86.
14. Montano-Loza AJ. Muscle wasting: a nutritional criterion to prioritize patients for liver transplantation. Curr Opin Clin Nutr Metab Care 2014; 17: 219-25.
15. Masuda T, Shirabe K, Ikegami T, Harimoto N, Yoshizumi T, Soejima Y, et al. Sarcopenia is a prognostic factor in living donor liver transplantation. Liver Transplant 2014; 20: 401-7.
16. Tsien C, Shah SN, McCullough AJ, Dasarathy S. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroen Hepat 2013; 25: 85-93.
17. Durand F, Buyse S, Francoz C, Laouenan C, Bruno O, Belghiti J, et al. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. J Hepatol 2014; 60: 1151-7.
18. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008; 33: 997-1006.
19. Dasarathy S. Consilience in sarcopenia of cirrhosis. J Cachexia Sarcopenia Muscle 2012; 3: 225-37.
20. Lang PO, Michel JP, Zekry D. Frailty syndrome: a transitional state in a dynamic process. Gerontology 2009; 55: 539-49.
21. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998; 147: 755-63.
22. Lang T, Streeper T, Cawthon P, Baldwin K, Taaffe DR, Harris TB. Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporos Int 2010; 21: 543-59.
23. Janssen I. Evolution of sarcopenia research. Appl Physiol Nutr Metab 2010; 35: 707-12.
24. Schrager MA, Metter EJ, Simonsick E, Ble A, Bandinelli S, Lauretani F, et al. Sarcopenic obesity and inflammation in the InCHIANTI study. J Appl Physiol 2007; 102: 919-25.
25. Kim TN, Park MS, Lim KI, Choi HY, Yang SJ, Yoo HJ, et al. Relationships between sarcopenic obesity and insulin resistance, inflammation, and vitamin D status: the Korean Sarcopenic Obesity Study. Clin Endocrinol (Oxf) 2013; 78: 525-32.
26. Gallagher D, Kuznia P, Heshka S, Albu J, Heymsfield SB, Goodpaster B, et al. Adipose tissue in muscle: a novel depot similar in size to visceral adipose tissue. Am J Clin Nutr 2005; 81: 903-10.
27. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003; 300: 1140-2.
28. Visser M, Goodpaster BH, Kritchevsky SB, Newman AB, Nevitt M, Rubin SM, et al. Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons. J Gerontol A Biol Sci Med Sci 2005; 60: 324-33.
29. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol 1998; 85: 115-22.
30. Kvist H, Sjostrom L, Tylen U. Adipose tissue volume determinations in women by computed tomography: technical considerations. Int J Obes 1986; 10: 53-67.
31. Vehmas T, Kairemo KJ, Taavitsainen MJ. Measuring visceral adipose tissue content from contrast enhanced computed tomography. Int J Obes Relat Metab Disord 1996; 20: 570-3.
32. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013; 31: 1539-47.
33. Vaughan VC, Martin P, Lewandowski PA. Cancer cachexia: impact, mechanisms and emerging treatments. J Cachexia Sarcopenia Muscle 2013; 4: 95-109.
34. Merli M, Lucidi C, Giannelli V, Giusto M, Riggio O, Falcone M, et al. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol 2010; 8: 979-85.
35. Owen OE, Reichle FA, Mozzoli MA, Kreulen T, Patel MS, Elfenbein IB, et al. Hepatic, gut, and renal substrate flux rates in patients with hepatic cirrhosis. J Clin Invest 1981; 68: 240-52.
36. Kondrup J, Nielsen K, Hamberg O. Nutritional therapy in patients with liver cirrhosis. Eur J Clin Nutr 1992; 46: 239-46.
37. Beyer I, Mets T, Bautmans I. Chronic low-grade inflammation and age-related sarcopenia. Curr Opin Clin Nutr Metab Care 2012; 15: 12-22.
38. Dasarathy S, McCullough AJ, Muc S, Schneyer A, Bennett CD, Dodig M, et al. Sarcopenia associated with portosystemic shunting is reversed by follistatin. J Hepatol 2011; 54: 915-21.
39. Taylor WE, Bhasin S, Artaza J, Byhower F, Azam M, Willard DH Jr, et al. Myostatin inhibits cell proliferation and protein synthesis in C2C12 muscle cells. Am J Physiol Endocrinol Metab 2001; 280: E221-8.
40. Qiu J, Tsien C, Thapalaya S, Narayanan A, Weihl CC, Ching JK, et al. Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. Am J Physiol Endocrinol Metab 2012; 303: E983-93.
41. Montano-Loza AJ, Meza-Junco J, Prado CM, Tandon P, Bain VG, Ma M, et al. New cutoff values for sarcopenia for predicting 6-months mortality in cirrhotic patients. J Hepatol 2013; 58: S95.
42. Montano-Loza AJ, Meza-Junco J, Baracos VE, Prado CM, Ma M, Meeberg G, et al. Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. Liver Transpl 2014; 20: 640-8.